Evidence map›Paper›PMID 35342088›Full record

ArticleJournal of Alzheimer's disease : JAD2022

Enhanced Association of Tau Pathology and Cognitive Impairment in Mild Cognitive Impairment Subjects with Behavior Symptoms.

Xinting Ge, Yuchuan Qiao, Jiyoon Choi, Rema Raman, John M Ringman, Yonggang Shi, for Alzheimer’s Disease Neuroimaging Initiative

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of Alzheimer's disease : JAD, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Xinting GeLaboratory of Neuro Imaging (LONI), Stevens Neuroimaging and Informatics Institute, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Yuchuan QiaoLaboratory of Neuro Imaging (LONI), Stevens Neuroimaging and Informatics Institute, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Jiyoon ChoiAlzheimer's Therapeutic Research Institute, Keck School of Medicine, University of Southern California, San Diego, CA, USA.
Rema RamanAlzheimer's Therapeutic Research Institute, Keck School of Medicine, University of Southern California, San Diego, CA, USA.
John M RingmanDepartment of Neurology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Yonggang ShiLaboratory of Neuro Imaging (LONI), Stevens Neuroimaging and Informatics Institute, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
for Alzheimer’s Disease Neuroimaging Initiative
University of Southern California · USAutism Research Institute · US

Funding

Alzheimer's Disease Neuroimaging Initiative - SupplementU01AG024904 · NIA · NORTHERN CALIFORNIA INSTITUTE RES &EDUC · PI WEINER, MICHAEL W · 2004 to 2015
$121.0M
USCADRC Diversity Supplement PachicanoP30AG066530 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI HELENA Chang CHUI, ARTHUR W TOGA · 2020 to 2026
$27.8M
TR&D3: Intrinsic Surface MappingP41EB015922 · NIBIB · UNIVERSITY OF SOUTHERN CALIFORNIA · PI VAN HORN, JOHN DARRELL · 2012 to 2022
$14.1M
Motor, Visual, and Olfactory Changes in Genetic Subtypes of Alzheimer’s DiseaseR01AG062007 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI RINGMAN, JOHN M · 2019 to 2023
$4.1M
Surface-Based Fiber Tracking and Modeling Techniques for Mapping the Superficial White Matter Connectome with Diffusion MRIR01EB022744 · NIBIB · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Yonggang Shi · 2016 to 2026
$3.7M
The structural and functional connectome across Alzheimer's disease subtypesU01AG051218 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI RINGMAN, JOHN M · 2015 to 2018
$3.6M
Brainstem connectomes related to Alzheimer's diseaseRF1AG056573 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI SHI, YONGGANG · 2018 to 2018
$2.5M
Tau-induced connectome imaging markers of Alzheimer's diseaseRF1AG064584 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI SHI, YONGGANG · 2020 to 2020
$2.1M
Tau-associated pathological changes in reward networks for the prediction of neuropsychiatric symptoms in Alzheimer’s diseaseR21AG064776 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI SHI, YONGGANG · 2019 to 2020
$444k
NIA NIH HHS P30 AG066530NIA NIH HHS R01 AG062007NIA NIH HHS R21 AG064776NIA NIH HHS RF1 AG056573NIA NIH HHS RF1 AG064584NIA NIH HHS U01 AG024904NIA NIH HHS U01 AG051218NIBIB NIH HHS P41 EB015922NIBIB NIH HHS R01 EB022744
6 · The paper itself

Abstract

backgroundMild cognitive impairment (MCI) individuals with neuropsychiatric symptoms (NPS) are more likely to develop dementia.

objectiveWe sought to understand the relationship between neuroimaging markers such as tau pathology and cognitive symptoms both with and without the presence of NPS during the prodromal period of Alzheimer's disease.

methodsA total of 151 MCI subjects with tau positron emission tomographic (PET) scanning with 18F AV-1451, amyloid-β (Aβ) PET scanning with florbetapir or florbetaben, magnetic resonance imaging, and cognitive and behavioral evaluations were selected from the Alzheimer's Disease Neuroimaging Initiative. A 4-group division approach was proposed using amyloid (A-/A+) and behavior (B-/B+) status: A-B-, A-B+, A+B-, and A+B+. Pearson's correlation test was conducted for each group to examine the association between tau deposition and cognitive performance.

resultsNo statistically significant association between tau deposition and cognitive impairment was found for subjects without behavior symptoms in either the A-B-or A+B-groups after correction for false discovery rate. In contrast, tau deposition was found to be significantly associated with cognitive impairment in entorhinal cortex and temporal pole for the A-B+ group and nearly the whole cerebrum for the A+B+ group.

conclusionEnhanced associations between tauopathy and cognitive impairment are present in MCI subjects with behavior symptoms, which is more prominent in the presence of elevated amyloid pathology. MCI individuals with NPS may thus be at greater risk for further cognitive decline with the increase of tau deposition in comparison to those without NPS.

Indexed as

Alzheimer DiseaseCognitive DysfunctionAmyloid beta-PeptidesHumansPositron-Emission Tomographytau ProteinsAmyloid beta-Peptidestau ProteinsAlzheimer’s diseasecognitive impairmentneuropsychiatric symptomstau-PET imaging

Identifiers

PMID35342088
PMCPMC9548450
OpenAlexW4220760227

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.